Quadrivalent HPV Vaccine Effectiveness Against Cervical Intraepithelial Lesion Grade 2 or Worse in Norway: A Registry-Based Study of 0.9 Million Norwegian Women.

Autor: Orumaa M; Department of Research, Cancer Registry of Norway, Oslo, Norway., Lahlum EJ; Department of Research, Cancer Registry of Norway, Oslo, Norway., Gulla M; Department of Research, Cancer Registry of Norway, Oslo, Norway., Tota JE; Merck & Co, Inc, Rahway, New Jersey, USA., Nygård M; Department of Research, Cancer Registry of Norway, Oslo, Norway., Nygård S; Department of Research, Cancer Registry of Norway, Oslo, Norway.
Jazyk: angličtina
Zdroj: The Journal of infectious diseases [J Infect Dis] 2024 Dec 16; Vol. 230 (6), pp. e1202-e1206.
DOI: 10.1093/infdis/jiae209
Abstrakt: In Norway, single-cohort vaccination with quadrivalent human papillomavirus (qHPV) vaccine targeting 12-year-old girls took place in 2009-2016. In 2020, the oldest vaccinated cohort was 23 years old and had approached the age where risk of being diagnosed with cervical intraepithelial neoplasia grade 2 or worse (CIN2+) increases rapidly. The aim of this cohort study was to assess direct qHPV vaccine effectiveness (VE) against CIN2+ among Norwegian women aged 16-30 years in 2007-2020. By using population-based health registries and individual-level data on vaccination status and potential subsequent CIN2+ incidence, we found 82% qHPV VE among women vaccinated before age 17 years.
Competing Interests: Potential conflicts of interest. J. E. T. is an employee of Merck Sharp & Dohme, LLC, a subsidiary of Merck & Co, Inc, Rahway, NJ. The affiliated institute of M. O., E. J. L., M. G., M. N., and S. N. has received research grants from MSD (Norge) AS. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
(© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America.)
Databáze: MEDLINE